Genetic polymorphisms at 19q13.33 are associated with [-2] proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer

Da Huang MD1 | Xiaohao Ruan MD1 | Yishuo Wu MD, PhD2 | Xiaoling Lin PhD2 | Jingyi Huang MD1 | Dingwei Ye MD, PhD3 | Yi Gao MD, PhD1 | Qiang Ding MD, PhD4 | Danfeng Xu MD, PhD1 | Rong Na MD, PhD1

1Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
3Department of Urology, Shanghai Cancer Center, Fudan University, Shanghai, China
4Shanghai Medical College, Fudan University, Shanghai, China

Correspondence
Rong Na, MD, PhD and Danfeng Xu, MD, PhD, Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Rd, Shanghai 200025, China.
Email: narong.hs@gmail.com and xdf12036@rjh.com.cn
Qiang Ding, MD, PhD, Shanghai Medical College, Fudan University, 138 Yixueyuan Rd, Shanghai 200032, China.
Email: qiangd.urol@gmail.com

Funding information
Shanghai Jiao Tong University School of Medicine, Grant/Award Number: 20181701; Shanghai Rising-Star Program, Grant/Award Number: 18QA1402800; Shanghai Municipal Education Commission, Grant/Award Number: 17CG09; Shanghai Municipal Human Resources and Social Security Bureau, Grant/Award Number: 2018052; National Natural Science

Abstract
Background: Prostate health index (phi), a derivative of [-2]proPSA (p2PSA), has shown better accuracy than prostate-specific antigen (PSA) in prostate cancer (PCa) detection. The present study was to investigate whether previously identified PSA-associated single nucleotide polymorphisms (SNPs) influence p2PSA or phi levels and lead to potential clinical utility.

Methods: We conducted an observational prospective study with 2268 consecutive patients who underwent prostate biopsy in three tertiary medical centers from August 2013 to March 2019. Genotyping data of the 46 candidate genes with a ± 100 kb window were tested for association with p2PSA and phi levels using linear regression. Multivariable logistic regression models were performed and internally validated using repeated tenfold cross-validation. We further calculated personalized phi cutoff values based on the significant genotypes. Discriminative performance was assessed using decision curve analysis and net reclassification improvement (NRI) index.

Results: We detected 11 significant variants at 19q13.33 which were p2PSA-associated independent of PCa. The most significant SNP, rs198978 in KLK2 ($P_{\text{combined}} = 5.73 \times 10^{-9}$), was also associated with phi values ($P_{\text{combined}} = 3.20 \times 10^{-6}$). Compared to the two commonly used phi cutoffs of 27.0 and 36.0, the personalized phi cutoffs had a significant NRI for PCa ranged from 5.23% to 9.70% among men carrying variant types (all $p < .01$).

Conclusion: Rs198978, is independently associated with p2PSA values, and can improve the diagnostic ability of phi for PCa using personalized cutoff values.

Da Huang, Xiaohao Ruan, and Yishuo Wu contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. The Prostate Published by Wiley Periodicals LLC
1 | INTRODUCTION

Prostate-specific antigen (PSA) is the most widely used biomarker for screening of prostate cancer (PCa). However, its poor ability to distinguish aggressive PCa from indolent diseases leads to a massive overdiagnosis.\(^2\) To solve these clinical predicaments, prostate health index (phi) derived from total PSA (tPSA), free PSA (fPSA), and proPSA (p2PSA), has been introduced. It has shown better accuracy in predicting PCa and clinically significant PCa (csPCa) than PSA, especially in patients with tPSA between 2.0 and 10 ng/ml.\(^2,4\) Our previous study also reported that phi outperformed PSA among Chinese men with tPSA > 10 ng/ml.\(^4\)

In the recent decade, plenty of single nucleotide polymorphisms (SNPs) have been reported to be associated with tPSA or fPSA levels in genome-wide association studies (GWAS) among PCa cases and controls.\(^8\) These variants have potentially important clinical implications if they are independently associated with biomarker levels (but not with PCa risk). For example, the genetic-adjusted PSA based on these SNPs can improve predictive performance by applying personalized cutoff values.\(^17\)\(^–\)\(^20\) Furthermore, previous non-GWAS association studies reported several genetic variants associated with serum hK2 levels.\(^21\)\(^–\)\(^24\) Thus, the correlative genetic variants may also affect the levels of serum p2PSA. However, the genetic or inherited influence on p2PSA levels is poorly understood and has never been reported.

The objective of this study is to investigate whether the established tPSA- and fPSA-associated SNPs are also independently associated with p2PSA or phi levels. To implement the results to clinical translational practice, we also assessed the clinical utility of personalized phi cutoffs adjusted by the genetic variants.

2 | MATERIALS AND METHODS

2.1 | Study population

In this prospective, observational study, we established a multicenter prostate biopsy cohort from three tertiary medical centers (Shanghai Ruijin Hospital, Shanghai Huashan Hospital, and Shanghai Cancer Center) in Shanghai, China. A total of 2268 patients who underwent initial prostate biopsies were consecutively enrolled from August 2013 to March 2019. This is a subset of the entire cohort with the information of genotyping array data.

The indications for prostate biopsy were the same across different centers: (1) a tPSA level > 10.0 ng/ml; (2) a tPSA level > 4.0 ng/ml with confirmation after 2–3 months; (3) %fPSA < 0.16 when patients had a tPSA level > 4.0 ng/ml; and (4) the presence of suspicious lesions detected by digital rectal examination (DRE), ultrasound or magnetic resonance imaging (MRI) at any level of tPSA. The phi calculation was not used in clinical decision-making. MRI was not used for biopsy decision-making in patients with a tPSA level > 4.0 ng/ml.

Blood samples were collected for genotyping and the measurement of tPSA, fPSA, and p2PSA before biopsies on the same day in a central certified lab per the study protocol. Transrectal ultrasound-guided biopsies were performed using a 10- to 14-core scheme. All biopsy specimens were independently examined and graded by two experienced pathologists in the department of pathology at each hospital. Based on the new Gleason grading system in 2015, csPCa was defined as PCa with Gleason Grade ≥ 3 (as known as Gleason Scores 4 + 3, 8, 9, and 10).\(^25\)

Patients were excluded from the present study if serum antigen levels (tPSA, fPSA, or p2PSA) were unable to be tested due to poor serum sample quality. The study was approved by the Institutional Review Board of each hospital, and written informed consent was obtained from each participant.

2.2 | SNP selection and genotyping

Genotyping was performed using the Illumina Asian Screening Array (ASA) BeadChip platform covering ~660k variants across the genome. Using the combined data of the 1000 Genomes project and HapMap3 data as reference, genotypes of SNPs that were not genotyped were imputed by IMPUTE version 2 software.\(^26\) A posterior probability of >0.90 was applied to call genotypes during imputation and the same quality control procedure for excluding genotyped SNPs was applied to imputed SNPs.

We selected 81 tPSA- or %fPSA-associated SNPs in 46 candidate genes and their intergenic regions from previous GWAS studies (Table S1).\(^8\)\(^–\)\(^18\) Genotyping data of the 46 candidate genes with a ± 100 kb window was extracted. SNPs were excluded if they had: (1) genotype call rate < 90% (n = 6833); (2) minor allele frequency (MAF) < 0.01 (n = 5989); or (3) p < 0.05 for the Hardy–Weinberg Equilibrium (HWE) test (n = 1250).

2.3 | Quantitative association analysis

The derivative variable phi was calculated as follows: \(\frac{\text{p2PSA}}{\text{tPSA}} \times \sqrt{\text{fPSA}}\). All the serum indices (including tPSA, fPSA, p2PSA,
and phi) were logarithm- (log-) transformed before quantitative association analyses. We randomly divided the entire cohort into two groups and performed a two-stage association study by using PLINK software (version 1.07).27 At each stage, multivariable linear regression analyses were used to evaluate the effect (beta values [β] and standard error) of each SNP on p2PSA or phi levels after adjusting for age and biopsy outcomes (PCa/non-PCa), and an additive model for allelic effect was assumed. The meta-analysis of the two subgroups was performed and P-combined values were estimated using the random-effects model. A p < .05 was considered statistically significant after the Bonferroni correction. Using the CHB population (Han Chinese in Beijing, China) as reference, the p value results and linkage disequilibrium patterns for SNPs in a region of interest were measured and visualized by LDassoc and LDmatrix Tool.28,29

2.4 Genetic-adjusted p2PSA/phi values and personalized cutoff values

The genetic correction of p2PSA levels was calculated as follows. First, subtract the log-transformed original p2PSA levels with the estimated relative genetic effects of the p2PSA-associated SNPs (β values in multivariable linear regression models); Second, take reverse log-transformation as the final genetic-adjusted p2PSA values. The genetic-adjusted phi values were calculated in the same way.

Using the three commonly used phi cutoffs (27, 36, and 55)30,31 as reference, personalized cutoff values for phi were calculated for each subject. The personalized cutoff values were determined by keeping the same level of specificity in patients with or without genetic variants.

2.5 Statistical analysis

For baseline characteristics, continuous variables were compared using Student's t-test after log-transformation or Cuzick's test for trend across ordered groups (SNP genotypes: wild type, heterozygous, and homozygous variant type). Categorical variables were compared using Fisher’s exact test. Ordinal variables were compared using Cochran–Armitage tests for trend. To evaluate whether an SNP of interest provides additional predictive value for PCa and csPCa, we conducted multivariable logistic regression (LR) models including age, phi, values, and SNP genotypes as covariates, and calculated adjusted odds ratios (aOR), 95% confidence intervals (95% CI) and p values for each covariate. The predictive abilities of phi, genetic-adjusted phi, and LR models were evaluated using the area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA).22 All the LR models were corrected for overfit by using repeated tenfold cross-validation (200 replications) before comparison. The net reduction in the number of biopsies between different models was also evaluated by DCA. Comparing to a commonly used phi cutoff, the performance of the personalized cutoff was evaluated using the net reclassification improvement (NRI) index.22 A Z-test was used to test for the null hypothesis of NRI = 0.

All statistical analyses were performed using Stata 15.1 Special Edition (StataCorp). A two-tailed p < .05 was considered statistically significant.

3 RESULTS

The baseline characteristics and biopsy outcomes in the entire cohort and subgroups of two stages are shown in Table S2. Based on our exclusion criteria, 14 patients were excluded due to the failure of serum antigen test, and 2254 patients with sufficient phenotypic and genotypic information were included for further association analyses. A total of 974 (43.2%) patients had PCa documented on biopsy, and 529 (23.5%) had csPCa. There were no significant differences in the baseline and outcomes between subjects in the two stages (All p > .05).

After quality control of genotyping results and imputed SNPs, a total of 15,433 SNPs in 2254 subjects was used for further association analyses. We evaluated the quantitative association between each individual SNP on p2PSA and phi levels at each stage adjusted for age and biopsy outcomes (Table 1). When the two stages were combined, we found that 11 SNPs in chromosome 19 were significantly associated with p2PSA levels at a P combined value < 3.24 × 10−6 (Bonferroni corrected significant level = 0.05/15,433). Among the 11 significant variants, there were 8 SNPs in the KLK2 gene and 3 in the KLKP1 gene. All of the 11 SNPs were in the same linkage disequilibrium (LD) region, with r2 values ranging from 0.907 to 0.969 (Figure 1). The most significant SNP, rs198978 (G > T) in the KLK2 gene at 19q13.33, was also the only SNP that was significantly associated with phi values (P combined = 5.73 × 10−9 and 3.20 × 10−6 for p2PSA and phi, respectively, Table 1). These indicated that the SNPs were independently associated with p2PSA and phi values regardless of the disease status (PCa/non-PCa).

We then performed a stratified analysis based on rs198978 genotypes in the entire cohort and patients with tPSA levels of 2–10 ng/ml. In the entire cohort, men carrying heterozygous and homozygous variant types (TT and TG) had significantly higher fPSA, p2PSA, and phi values than those with wild type (all p < .05, Table S3). In addition, p2PSA and phi values both had increased significantly across ordered genotype groups (all p for trend < .001, Table 2). The genotype’s effect on p2PSA and phi values remained significant in PCa and non-PCa groups (Table S4). However, no significant difference was observed in age and tPSA values among different rs198978 genotypes (all p > .05, Table S3). Similar results were also found among patients with tPSA levels of 2–10 ng/ml.

The association between the loci at 19q13.33 and PCa risk was shown in Table 2. In univariate analysis, no significant difference was observed in the incidence of PCa and csPCa between men with different rs198978 genotypes (GG vs. TG vs. TT, p for trend = .685
**TABLE 1** Summary results of SNPs associated with p2PSA and prostate health index (phi) values at genome-wide significant level (P < 3.24 × 10⁻⁶)

| SNP    | Region  | Position | Alleles | Gene   | Consequence           | Stage | log-transformed p2PSA β (SE) | p     | P<sub>combined</sub> | log-transformed phi β (SE) | p    | P<sub>combined</sub> |
|--------|---------|----------|---------|--------|------------------------|-------|-----------------------------|-------|-----------------------|-----------------------------|------|--------------------|
| rs6070 | 19q13.33| 51,380,110| A/T     | KLK2   | Intron variant         | 1     | 0.13 (0.03)                  | 3.09E-05 | 1.70E-08              | 0.08 (0.02)                  | 4.73E-04 | 1.20E-05           |
|        |         |          |         |        |                        | 2     | 0.12 (0.03)                  | 1.63E-04 | 0.06 (0.02)              | .008                        |      |                    |
| rs8105275 | 19q13.33 | 51,380,445 | T/G     | KLK2   | Intron variant         | 1     | 0.14 (0.03)                  | 2.01E-05 | 4.35E-08              | 0.08 (0.02)                  | 5.57E-04 | 2.50E-05           |
|        |         |          |         |        |                        | 2     | 0.11 (0.03)                  | 5.71E-04 | 0.06 (0.02)              | .013                        |      |                    |
| rs198974 | 19q13.33 | 51,380,602 | G/T     | KLK2   | Intron variant         | 1     | 0.13 (0.03)                  | 2.45E-05 | 1.67E-08              | 0.08 (0.02)                  | 2.13E-04 | 1.06E-05           |
|        |         |          |         |        |                        | 2     | 0.12 (0.03)                  | 1.96E-04 | 0.06 (0.02)              | .013                        |      |                    |
| rs198975 | 19q13.33 | 51,380,815 | T/G     | KLK2   | Intron variant         | 1     | 0.13 (0.03)                  | 2.30E-05 | 2.71E-08              | 0.08 (0.02)                  | 1.91E-04 | 1.13E-05           |
|        |         |          |         |        |                        | 2     | 0.11 (0.03)                  | 3.23E-04 | 0.06 (0.02)              | .015                        |      |                    |
| rs8108845 | 19q13.33 | 51,381,083 | C/G     | KLK2   | Intron variant         | 1     | 0.14 (0.03)                  | 1.16E-05 | 3.25E-08              | 0.08 (0.02)                  | 2.09E-04 | 1.49E-05           |
|        |         |          |         |        |                        | 2     | 0.11 (0.03)                  | 6.71E-04 | 0.06 (0.02)              | .017                        |      |                    |
| rs198976 | 19q13.33 | 51,381,126 | T/C     | KLK2   | Intron variant         | 1     | 0.13 (0.03)                  | 2.22E-05 | 2.54E-08              | 0.08 (0.02)                  | 1.79E-04 | 1.21E-05           |
|        |         |          |         |        |                        | 2     | 0.11 (0.03)                  | 3.15E-04 | 0.05 (0.02)              | .016                        |      |                    |
| rs198977 | 19q13.33 | 51,381,777 | T/C     | KLK2   | NC transcript/Missense/3'-UTR variant | 1     | 0.13 (0.03)                  | 1.47E-05 | 1.23E-08              | 0.08 (0.02)                  | 2.84E-04 | 1.13E-05           |
|        |         |          |         |        |                        | 2     | 0.11 (0.03)                  | 2.23E-04 | 0.06 (0.02)              | .011                        |      |                    |
| rs198978 | 19q13.33 | 51,383,072 | T/G     | KLK2   | NC transcript/3'-UTR variant | 1     | 0.13 (0.03)                  | 3.40E-05 | 5.73E-09              | 0.08 (0.02)                  | 1.76E-04 | 3.20E-06           |
|        |         |          |         |        |                        | 2     | 0.12 (0.03)                  | 4.98E-05 | 0.06 (0.02)              | .005                        |      |                    |
| rs16987929 | 19q13.33 | 51,385,253 | G/A     | KLKP1  | Downstream variant     | 1     | 0.13 (0.03)                  | 1.93E-05 | 1.22E-08              | 0.08 (0.02)                  | 4.84E-04 | 1.49E-05           |
|        |         |          |         |        |                        | 2     | 0.11 (0.03)                  | 1.72E-04 | 0.06 (0.02)              | .009                        |      |                    |
| rs8103659 | 19q13.33 | 51,385,402 | G/A     | KLKP1  | NC transcript variant   | 1     | 0.13 (0.03)                  | 4.58E-05 | 3.40E-08              | 0.07 (0.02)                  | 6.82E-04 | 1.77E-05           |
|        |         |          |         |        |                        | 2     | 0.11 (0.03)                  | 2.14E-04 | 0.06 (0.02)              | .008                        |      |                    |
| rs198958 | 19q13.33 | 51,388,878 | A/T     | KLKP1  | Intron variant         | 1     | 0.10 (0.03)                  | 1.78E-03 | 2.74E-06              | 0.06 (0.02)                  | 7.20E-03 | 2.84E-04           |
|        |         |          |         |        |                        | 2     | 0.11 (0.03)                  | 4.96E-04 | 0.06 (0.02)              | .015                        |      |                    |

Abbreviations: 3'-UTR, three prime untranslated region; β, regression coefficient; p2PSA, [-2]proPSA; log, logarithm; NC, noncoding; phi, prostate health index; SE, standard error.

*P values were estimated using multivariate linear regression on logarithm-transformed p2PSA or phi values after adjusting for age and biopsy outcomes (prostate cancer or not), and an additive model for allelic effect was assumed. P<sub>combined</sub> values were estimated using random-effects meta-analysis across two-stage association studies.
and .093 for PCa and csPCa, respectively). Similar results were also observed in multivariable analysis on csPCa risk (all \( p > .05 \)). However, men carrying variant types showed a mildly lower positive biopsy rate (aOR_{T} = 0.79, 95% CI = 0.61–1.01, \( p = .064 \); aOR_{T} = 0.49, 95% CI = 0.27–0.89, \( p = .019 \)), compared with men carrying homozygous wild type after adjusting for age and \( \phi \) values.

The predictive abilities of different diagnostic models were compared in Figure 2. Briefly, the AUCs of genetic-adjusted p2PSA/\( \phi \) did not outperform original p2PSA/\( \phi \) for predicting PCa or csPCa (all \( p > .05 \), Figures 2A and 2B). Similar results were found among patients with tPSA levels of 2–10 ng/ml (Figures 2C and 2D). All the LR models did not outperform the base models (LR1 vs. \( \phi \); LR3 vs. LR2), which indicated that incorporating the genotypes might not improve the overall discriminating abilities of the original LR models.

After correction for overfit by cross-validation, net benefits of different diagnostic models are shown in Figure 3. In the entire cohort, the LR1 model (\( \phi \) + rs198978 genotype) could achieve a mildly higher net benefit than the original \( \phi \) for PCa risk thresholds between 20% and 35% (Figure 3A). For csPCa, the LR1 model had a higher net benefit than the original \( \phi \) across the entire spectrum of threshold probability (Figure 3B). However, no significant increase in net benefit was observed between the full model (LR3) and LR2 in either the entire cohort or patients with tPSA 2–10 ng/ml (Figures 3C and 3D).

To determine whether rs198978 genotype would provide additional predictive value to \( \phi \), we further calculated the personalized \( \phi \) cutoff values on the basis of three commonly used cutoffs (27, 36, and 55). Among men carrying variant types, using a \( \phi \) cutoff of 30.9 would cause 5.23% (\( p = .001 \)) of the
total population to reclassify into the correct biopsy decisions, compared with a commonly used cutoff of 27 (Table 3). Similarly, a \( p1\) cutoff of 42.2 would perform significantly better than the commonly used cutoff of 36 (NRI = 9.70%, \( p < .001\)). Similar results were found when predicting csPCa (all \( p < .001\)). However, among patients with \( p1\) levels of 2–10 ng/ml, no significant difference in discriminability between the personalized and the commonly used cutoffs (all \( p > .05\)). By applying the personalized cutoffs to men carrying variant types, higher net reduction in number of biopsies could be achieved at risk thresholds above 15% for PCA (Figures S1A and S1C) and approximately 10% for csPCA (Figures S1B and S1D). However, the personalized cutoffs could not improve the accuracy of the commonly used cutoff of 55, with negative NRI and net reduction in number of biopsies (Table 3 and Figure S1).

### TABLE 2 Association results for rs198978 genotypes with \( p1\) levels, prostate health index, and biopsy outcomes

| Rs198978 | Mean* \( p1\) | Mean* \( phi\) | PCA, n (%) | PCA vs. non-PCA aOR (95% CI) | \( p\) | csPCA, n (%) | csPCA vs. others aOR (95% CI) | \( p\) |
|----------|--------------|---------------|------------|-----------------------------|------|-------------|-----------------------------|------|
| **Entire cohort** | | | | | | | | |
| GG       | 1478         | 30.3          | 59.3       | 637 (43.1)                  | 1.00 (Ref.) | 335 (22.7) | 1.00 (Ref.) | 335 (22.7) | 1.00 (Ref.) |
| TG       | 620          | 42.7          | 71.3       | 275 (44.4)                  | 0.79 (0.61–1.01) | 0.64 | 160 (25.8) | 0.98 (0.73–1.33) | .904 |
| TT       | 83           | 52.1          | 84.6       | 36 (43.4)                  | 0.49 (0.27–0.89) | 0.019 | 21 (25.3) | 0.99 (0.52–1.91) | .985 |
| \( P\) for trend\( c\) | / | 8.22 \( \times 10^{-13}\) | 2.63 \( \times 10^{-6}\) | 0.685 | / | / | 0.093 | / | / |
| **\( p1\) levels of 2–10 ng/ml** | | | | | | | | |
| GG       | 513          | 12.5          | 33.2       | 122 (23.8)                  | 1.00 (Ref.) | 35 (7.2) | 1.00 (Ref.) | 35 (7.2) | 1.00 (Ref.) |
| TG       | 217          | 16.0          | 36.5       | 48 (22.1)                  | 0.71 (0.46–1.10) | 0.122 | 14 (6.7) | 0.76 (0.38–1.50) | .426 |
| TT       | 25           | 20.0          | 40.9       | 5 (20.0)                  | 0.47 (0.15–1.47) | 0.192 | 3 (12.5) | 1.39 (0.35–5.46) | .641 |
| \( P\) for trend\( c\) | / | 3.28 \( \times 10^{-11}\) | 9.77 \( \times 10^{-4}\) | 0.537 | / | / | 0.705 | / | / |

Abbreviations: 95% CI, 95% confidence interval; aOR, adjusted odds ratio; csPCA, clinically significant prostate cancer; \( p1\), prostate cancer; \( phi\), prostate health index; Ref, reference; \( p1\), total prostate-specific antigen.

*Both of the \( p1\) levels and \( phi\) were log-transformed before calculation and the values presented were back-transformed.

\( c\)Adjusted odds ratios were determined by multivariate logistic regression analysis after adjusting for age and log-transformed \( phi\) values.

\( d\)The \( p\) values for trend were determined by Cuzick’s test.

**4 | DISCUSSION**

In this two-stage tagged association study based on a multicenter cohort, we identified one independent locus at the KLK2 gene in 19q13.33 that was significantly associated with both \( p1\) and \( phi\) levels but not associated with PCA risk. Men carrying variant types (rs198978: G > T) had significantly higher \( p1\) and \( phi\) values than those with wild type. No significant association was observed between the detection rate of PCA/csPCA and rs198978 genotype. The adjusted cutoffs of \( phi\) outperformed the two commonly used one-size-fits-all cutoffs (27 and 36) in men with variant types. These findings may improve the clinical utility of \( phi\) in the detection of PCA and csPCA and help to avoid a large number of unnecessary biopsies.

An elevated biomarker, caused by genetic effects rather than oncogenesis, may decrease diagnostic accuracy due to more false-positive cases. Several previous studies reported the feasibility of incorporating genetic markers into PSA screening.34–37 One of the most commonly used methods was adding significant SNPs and PSA values into a multivariable model. However, all the previous studies demonstrated that adding SNPs to the predictive model would not significantly improve the discriminating abilities of PSA (with only marginal area under receiver operating characteristic curve [AUC] improvement around –0.02).34–37 Similarly, in the present study, multivariable LR model had a mildly higher net benefit than \( phi\) only in the entire cohort (Figure 2). The other method was establishing personalized cutoff values of PSA based on the cumulative effects of significant SNPs.17–20 For example, Gudmundsson et al.13 have identified four PSA-associated markers in a GWAS and calculated a personalized PSA cutoff value based on the distribution of genotypic effect, which showed that ~6%–7% had at least one PSA value reclassified into higher or lower PCA risk categories. We identified only one significant \( p1\)-associated locus in the present study. Thus, we did not estimate the cumulative effects, and calculated the adjusted cutoff values by keeping the same specificity of \( phi\) across rs198978 genotypes. Compared to the two traditional \( phi\) cutoff values of 27 and 36, the net reclassification percentage of our personalized \( phi\) cutoffs ranged from 5.23% to 9.70%, which were similar to the results by Gudmundsson et al.13 In summary, when evaluating the genetic adjusted biomarkers, the point
estimation method such as personalized cutoff and NRI might be more suitable than the overall estimation including AUC and multivariable regression models.

The underlying molecular mechanism of our findings is still unknown. In the present study, all the identified p2PSA-associated SNPs were at a strong LD block in a region incorporating KLK2 and KLKP1 gene, which both belonged to the kallikrein gene family on chromosome 19. The KLK2 gene encodes hK2 protein, which is the major activating enzyme for proPSA cleavage in vivo. The elevation of these truncated proPSA isoforms (such as p2PSA, also known as [-2]proPSA) may be associated with the downregulation of KLK2 gene. Previous studies have revealed that KLKP1 was a pseudogene of kallikreins, of which the expression level was lower in PCa cells than that in normal prostate cells and was regulated by androgen. In BPH samples, KLKP1 mRNA levels strongly correlated with PSA mRNA levels. However, further studies would be

FIGURE 2 ROC curves of different diagnostic models: (A) for PCa in entire cohort; (B) for csPCa in entire cohort; (C) for PCa in patients with tPSA 2–10 ng/ml; (D) for csPCa in patients with tPSA 2–10 ng/ml. AUC, area under the curve; csPCa, clinically significant prostate cancer; LR, logistic regression model; PCa, prostate cancer; tPSA, total prostate-specific antigen; p2PSA, [-2]proPSA; phi, prostate health index; Ref, reference [Color figure can be viewed at wileyonlinelibrary.com]
necessary to demonstrate the complex functional mechanism of KLK2 and KLKP1, which might regulate p2PSA expression through androgen receptor.

There were several limitations of this study. First, this is a tagged association study based on 46 candidate genes with a ± 100 kb window. Loci outside these regions might exist. However, this will not change the implementation of our current findings to clinical practice in terms of personalized cutoffs. Second, the sample size of patients with tPSA values of 2–10 ng/ml was relatively small, which might be due to the high likelihood of high-grade PCa in China compared to Western populations.41 However, phi performed better than PSA in patients with higher tPSA levels (>10 ng/ml) in the Chinese population. The application of p2PSA testing is not limited to PSA grey zone in China at this stage. Therefore, we also performed the current analyses in the entire cohort. Third, both the association study and modeling were performed in the same cohort, which might

FIGURE 3 Decision curve analysis. Net benefit of different diagnostic models: (A) for PCa in entire cohort; (B) for csPCa in entire cohort; (C) for PCa in patients with tPSA 2–10 ng/ml; (D) for csPCa in patients with tPSA 2–10 ng/ml. csPCa, clinically significant prostate cancer; LR, logistic regression model; PCa, prostate cancer; phi, prostate health index; tPSA, total prostate-specific antigen. aAll the LR models were corrected for overfit by using repeated tenfold cross-validation (200 replications) [Color figure can be viewed at wileyonlinelibrary.com]
| Traditional cutoffs | Wild type (rs198978: GG) | Variant types (rs198978: G > T) |
|--------------------|-------------------------|-------------------------------|
|                    | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | NRI (%) | P NRI |
| Entire cohort: predict PCa | | | | | | | | | |
| 27.0               | 94.5          | 35.4          | 52.7    | 89.4    | 27.0 (Ref.)     | 97.7          | 25.8    | 51.2    | 93.5    | 5.23  | 0.001 |
| 30.9               | 95.8          | 35.5          | 54.2    | 91.4    |                 |               |         |         |         |       |       |
| 36.0               | 88.8          | 58.8          | 62.2    | 87.3    | 36.0 (Ref.)     | 93.6          | 46.3    | 58.1    | 90.0    | 9.70  | <0.001|
| 42.2               | 91.0          | 58.6          | 63.6    | 89.1    |                 |               |         |         |         |       |       |
| 55.0               | 74.4          | 82.3          | 76.2    | 80.8    | 55.0 (Ref.)     | 83.9          | 79.8    | 76.8    | 86.2    | −0.66 | 0.613 |
| 60.1               | 80.7          | 82.4          | 78.4    | 84.3    |                 |               |         |         |         |       |       |
| Entire cohort: predict csPCa | | | | | | | | | |
| 27.0               | 97.6          | 30.9          | 31.4    | 97.6    | 27.0 (Ref.)     | 98.9          | 22.6    | 33.2    | 98.1    | 7.83  | <0.001|
| 30.6               | 98.3          | 31.0          | 35.7    | 98.0    |                 |               |         |         |         |       |       |
| 36.0               | 93.4          | 51.4          | 38.4    | 96.0    | 36.0 (Ref.)     | 96.7          | 41.5    | 39.1    | 97.0    | 8.02  | <0.001|
| 41.5               | 95.0          | 51.2          | 43.1    | 96.4    |                 |               |         |         |         |       |       |
| 55.0               | 86.9          | 75.3          | 53.3    | 94.7    | 55.0 (Ref.)     | 90.6          | 73.1    | 56.7    | 95.2    | −0.61 | 0.665 |
| 59.7               | 87.8          | 75.3          | 58.0    | 94.1    |                 |               |         |         |         |       |       |
| tPSA 2–10 ng/ml: predict PCa | | | | | | | | | |
| 27.0               | 85.2          | 43.5          | 32.0    | 90.4    | 27.0 (Ref.)     | 88.7          | 28.0    | 25.7    | 89.8    | 7.80  | 0.099 |
| 30.6               | 81.1          | 43.4          | 28.7    | 89.1    |                 |               |         |         |         |       |       |
| 36.0               | 68.9          | 69.1          | 41.0    | 87.7    | 36.0 (Ref.)     | 71.7          | 55.6    | 31.1    | 87.5    | 8.10  | 0.056 |
| 41.6               | 66.0          | 69.3          | 37.6    | 87.9    |                 |               |         |         |         |       |       |
| 55.0               | 38.5          | 91.6          | 58.8    | 82.7    | 55.0 (Ref.)     | 41.5          | 90.5    | 55.0    | 84.7    | −4.60 | 0.170 |
| 58.1               | 35.8          | 91.5          | 54.3    | 83.6    |                 |               |         |         |         |       |       |
| tPSA 2–10 ng/ml: predict csPCa | | | | | | | | | |
| 27.0               | 91.4          | 40.7          | 10.7    | 98.4    | 27.0 (Ref.)     | 88.2          | 26.5    | 8.7     | 96.6    | 8.07  | 0.208 |
| 30.5               | 82.4          | 40.5          | 9.9     | 96.7    |                 |               |         |         |         |       |       |
| 36.0               | 71.4          | 65.1          | 13.7    | 96.7    | 36.0 (Ref.)     | 70.6          | 53.5    | 10.7    | 95.8    | −0.14 | 0.988 |
| 41.3               | 58.8          | 65.1          | 11.8    | 95.2    |                 |               |         |         |         |       |       |

(Continues)
ead to an over-estimate. Although the internal tenfold cross-validation has been performed in the present study, further external validation is needed if applicable. Fourth, the present study may have selection bias because all the three hospitals were located in Shanghai, a large city in East China. However, nearly half of the patients seeking services in these tertiary hospitals were from provinces other than Shanghai.

5 | CONCLUSIONS

A locus at 19q13.33 (rs198978) is identified to be associated with p2PSA and phi levels but not PCa risk. Personalized phi cutoff values, based on the genotype, would improve the predictive accuracy of phi in the decision-making for prostate biopsy.

ACKNOWLEDGMENTS

The authors thank all the subjects included in this study. This study was in part supported by grants from the National Natural Science Foundation of China (Grant nos. 81772741, 81972645, and 81972405), Shanghai Rising-Star Program (Grant no. 18QA1402800), the “Chen Guang” project from Shanghai Municipal Education Commission, and Shanghai Education Development Foundation (Grant no. 17CG09), Shanghai Jiao Tong University School of Medicine Gaofeng-Clinical Medicine Grant Support (Grant no. 20181701), and Shanghai Municipal Human Resources and Social Security Bureau (Grant no. 2018052).

CONFLICT OF INTEREST

In the present study, we declare that Beckman Coulter, Inc. provided the tests for tPSA, fPSA, and p2PSA. All the sample collection, data analyses, and manuscript writing were performed by the researchers, independent from Beckman Coulter, Inc. There are no other potential competing interests to be declared.

ETHICS STATEMENT

The study was approved by the Institutional Review Board of Shanghai Ruijin Hospital, Shanghai Huashan Hospital, and Shanghai Cancer Center in Shanghai, China, and written informed consent was obtained from each participant (Central IRB no. KY2016-343, November 24, 2016, version 03).

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ORCID

Da Huang http://orcid.org/0000-0002-6203-9459
Xiaohao Ruan http://orcid.org/0000-0001-8373-5237
Jingyi Huang http://orcid.org/0000-0001-5590-8954
Danfeng Xu http://orcid.org/0000-0002-4175-1009
Rong Na http://orcid.org/0000-0001-7470-5108
REFERENCES
1. Draisma G, Boer R, Otto SJ, et al. Lead times and overdiagnosis due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878.
2. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2] pro‐prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650-1655.
3. Guazzoni G, Nava L, Lazzari M, et al. Prostate‐specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol. 2011;60(2):214-222.
4. Na R, Ye D, Qi J, et al. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. Prostate. 2017;77(11):1221-1229.
5. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate‐specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997;57(15):3111-3114.
6. Mikolajczyk SD, Marker KM, Millar LS, et al. A truncated precursor form of prostate‐specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001;61(18):6958-6963.
7. Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate‐specific antigen and tissue kallikreins. Eur Urol. 2009;55(3):563-574.
8. Kim S, Shin C, Jee SH. Genetic variants at 1q32.1, 10q11.2 and 19q13.41 are associated with prostate‐specific antigen for prostate cancer screening in two Korean population‐based cohort studies. Gene. 2015;556(2):199-205.
9. Sun J, Tao S, Gao Y, et al. Genome‐wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate‐specific antigen (PSA) in a Chinese population. Hum Genet. 2013;132(4):423-429.
10. Hoffmann TJ, Passarelli MN, Graff RE, et al. Genome‐wide association study of prostate‐specific antigen levels identifies novel loci independent of prostate cancer. Nat Commun. 2017;8:14248.
11. Gudmundsson J, Sigurdsson JK, Stefansson T, et al. Genome‐wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat Commun. 2018;9(1):4568.
12. Eikes RA, Kote‐Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316-321.
13. Jin G, Zheng SL, Lilja H, et al. Genome‐wide association study identifies loci at ATCF71P and KLK2 associated with percentage of circulating free PSA. Neoplasia. 2013;15(11):95-101.
14. Kote‐Jarai Z, Amin Al Olama A, Leongamornlert D, et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet. 2011;129(6):687-694.
15. Bensen JT, Xu Z, Smith GJ, Mohler JL, Fontham ETH, Taylor JA. Genetic polymorphism and prostate cancer aggressiveness: a case‐only study of 1,536 GWAS and candidate SNPs in African‐Americans and European‐Americans. Prostate. 2013;73(1):11-22.
16. Haiman CA, Han Y, Feng Y, et al. Genome‐wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. PLOS Genet. 2013;9(3):e1003419.
17. Terao C, Terada N, Matsuo K, et al. A genome‐wide association study of serum levels of prostate‐specific antigen in the Japanese population. J Med Genet. 2014;51(8):530-536.
18. Gudmundsson J, besenbacher s, sulem p, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med. 2010;2(6):26ra92.
19. Chang B‐L, Hughes L, Chen DYT, Gross L, Ruth K, Giri VN. Validation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer. BJU Int. 2014;113(5b):E150-E156.
20. Donin NM, Loeb S, Cooper PR, et al. Genetically adjusted prostate‐specific antigen values may prevent delayed biopsies in African‐American men. BJU Int. 2014;114(6b):E50‐E53.
21. Nam RK, Zhang WW, Trachtenberg J, et al. Single nucleotide polymorphism of the human kallikrein‐2 gene highly correlates with serum human kallikrein‐2 levels and in combination enhances prostate cancer detection. J Clin Oncol. 2003;21(12):2312-2319.
22. Nam RK, Zhang WW, Klotz LH, et al. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res. 2006;12(21):6452-6458.
23. Klein RJ, Haldén C, Cronin AM, et al. Blood biomarker levels to aid discovery of cancer‐related single‐nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res. 2010;3(5):611-619.
24. Sävblom C, Haldén C, Cronin AM, et al. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men. Clin Chem. 2014;60(3):490-499.
25. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69(3):428-435.
26. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multi‐point method for genome‐wide association studies by imputation of genotypes. Nat Genet. 2007;39(7):906-913.
27. Purcell S, Neale B, Todd‐Brown K, et al. PLINK: a tool set for whole‐genome association and population‐based linkage analyses. Am J Hum Genet. 2007;81(3):559-575.
28. Machiela MJ, Chanock SJ. LDlink: a web‐based application for exploring population‐specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31(23):3555-3557.
29. Machiela MJ, Chanock SJ. LDassoc: an online tool for interactively exploring genome‐wide association study results and prioritizing variants for functional investigation. Bioinformatics. 2018;34(5):887-889.
30. Loeb S, Senda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193(4):1163-1169.
31. Beckman Coulter Access Hybritech p2PSA Instructions for Use. https://www.beckmancoulter.com/products/immunoassy/phi. Accessed October 5, 2020.
32. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565-574.
33. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172.
34. Nam RK, Zhang WW, Trachtenberg J, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res. 2009;15(5):1787-1793.
35. Klein RJ, Haldén C, Gupta A, et al. Evaluation of multiple risk‐associated single nucleotide polymorphisms versus prostate‐specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol. 2012;61(3):471-477.
36. Aly M, Wiklund F, Xu J, et al. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm‐1 cohort study. Eur Urol. 2011;60(1):21-28.
37. Johansson M, Holmström B, Hinchliffe SR, et al. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer. 2012;130(1):129-137.
38. Balk SP, Ko Y-J, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21(2):383-391.
39. Kaushal A, Myers SA, Dong Y, et al. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus. Prostate. 2008;68(4):381-399.
40. Lu W, Zhou D, Glusman G, et al. KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells. Prostate. 2006;66(9):936-944.
41. Chen R, Ren S, Chinese Prostate Cancer Consortium, et al. Prostate cancer in Asia: a collaborative report. Asian J Urol. 2014;1(1):15-29.

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Huang D, Ruan X, Wu Y, et al. Genetic polymorphisms at 19q13.33 are associated with [−2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer. The Prostate. 2021;81:971-982.
https://doi.org/10.1002/pros.24192